Medexus Pharma publishes FY 2026 MD&A report for year ended March 31, 2026

  • Medexus Pharmaceuticals published its MD&A for fiscal year 2026, highlighting a ramp in GRAFAPEX following its February 2025 US launch.
  • GRAFAPEX net revenue totaled USD 11.6 million; underlying patient demand was USD 10.6 million; wholesaler inventory was about one month.
  • Outlook calls for GRAFAPEX net revenue of USD 30-32 million in fiscal year 2027; quarterly launch investments seen at USD 3-4 million.
  • US uptake broadened to 56 institutions with formulary wins; 64 transplant centers ordered; 42 health plans established coverage pathways.
  • Company results showed net revenue of USD 99.3 million, adjusted EBITDA of USD 16.5 million, net loss of USD 2.4 million; pressure from Rupall generics, Gleolan exit.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medexus Pharmaceuticals Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.